Literature DB >> 8321046

Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders.

G Gaidano1, A Guerrasio, A Serra, F Carozzi, G R Cambrin, D Petroni, G Saglio.   

Abstract

We have investigated the involvement of the p53 tumor suppressor gene and RAS family proto-oncogenes in BCR/ABL-negative chronic myeloproliferative disorders (CMPD), including nine cases of myelosclerosis with myeloid metaplasia, four polycythemia vera, 10 essential thrombocythemia, one juvenile chronic myeloid leukemia, and eight BCR/ABL-negative chronic myeloid leukemia. Twenty-five samples were studied in the chronic phase, while seven samples were analyzed in the acute accelerated or blastic phase. The presence of mutations in p53 exons 5-9, as well as in N-, K-, H-Ras exons 1 and 2 (containing codons 12, 13, and 61) was tested by the polymerase chain reaction (PCR) single strand conformation polymorphism technique and by PCR direct sequencing. In addition, restriction analysis was performed to screen for gross rearrangements within the p53 locus. Alterations of the p53 tumor suppressor gene and Ras family proto-oncogenes were detected in 2/7 and 3/7 cases of acute phase BCR/ABL-negative CMPD, respectively, while consistently negative in all the chronic phase samples analyzed. These results suggest that p53 inactivation and/or Ras activation might play a role in acute transformation of BCR/ABL-negative CMPD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321046

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

2.  Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.

Authors:  G Gaidano; E W Newcomb; J Z Gong; V Tassi; A Neri; A Cortelezzi; R Calori; L Baldini; R Dalla-Favera
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

3.  Oral idasanutlin in patients with polycythemia vera.

Authors:  John Mascarenhas; Min Lu; Heidi Kosiorek; Elizabeth Virtgaym; Lijuan Xia; Lonette Sandy; Ruben Mesa; Bruce Petersen; Noushin Farnoud; Vesna Najfeld; Raajit Rampal; Amylou Dueck; Ronald Hoffman
Journal:  Blood       Date:  2019-06-05       Impact factor: 22.113

4.  Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.

Authors:  Despina Mavrogianni; Nora Viniou; Evi Michali; Evangelos Terpos; John Meletis; George Vaiopoulos; Marina Madzourani; Gerasimos Pangalis; Xenophon Yataganas; Dimitris Loukopoulos
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

5.  p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.

Authors:  M Kitagawa; S Yoshida; T Kuwata; T Tanizawa; R Kamiyama
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

6.  Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Nils H Thoennissen; Utz O Krug; Dhong Hyun Tony Lee; Norihiko Kawamata; Gabriela B Iwanski; Terra Lasho; Tamara Weiss; Daniel Nowak; Maya Koren-Michowitz; Motohiro Kato; Masashi Sanada; Lee-Yung Shih; Arnon Nagler; Sophie D Raynaud; Carsten Müller-Tidow; Ruben Mesa; Torsten Haferlach; D Gary Gilliland; Ayalew Tefferi; Seishi Ogawa; H Phillip Koeffler
Journal:  Blood       Date:  2010-01-12       Impact factor: 22.113

7.  Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.

Authors:  G Gaidano; A Serra; A Guerrasio; G Rege-Cambrin; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

8.  Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

Authors:  Fabio P S Santos; Bartlomiej Getta; Lucia Masarova; Christopher Famulare; Jessica Schulman; Tarcila S Datoguia; Renato D Puga; Raquel de Melo Alves Paiva; Maria E Arcila; Nelson Hamerschlak; Hagop M Kantarjian; Ross L Levine; Paulo Vidal Campregher; Raajit K Rampal; Srdan Verstovsek
Journal:  Leukemia       Date:  2019-10-18       Impact factor: 11.528

Review 9.  What are the molecular mechanisms driving the switch from MPNs to leukemia?

Authors:  Xiaoli Wang; Ronald Hoffman
Journal:  Best Pract Res Clin Haematol       Date:  2021-02-08       Impact factor: 3.020

10.  Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Authors:  B Kubesova; S Pavlova; J Malcikova; J Kabathova; L Radova; N Tom; B Tichy; K Plevova; B Kantorova; K Fiedorova; M Slavikova; V Bystry; J Kissova; B Gisslinger; H Gisslinger; M Penka; J Mayer; R Kralovics; S Pospisilova; M Doubek
Journal:  Leukemia       Date:  2017-07-24       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.